Mark Baker, MD
Urology · Riverview, FLNPI 1972599827
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (58.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.0% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $19,568, more than ten times the $1,170 reported in 2019. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $145.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$47K
- Johnson & Johnson$2K
- Janssen Scientific Affairs, LLC$818
- Angiodynamics, Inc.$776
- Teleflex LLC$643
- Procept Biorobotics Corporation$553
- plus $3K from 35 others
Across 2 payments — averaging $4165.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring Pharmaceuticals AS$8K
What the payments were for
- Consulting fees$8182%
- Speaking & faculty fees$11,00020%
- Travel & lodging$2,4455%
- Food & beverage$8,06915%
- Education$31,78259%
- Gifts$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 52 | $46,714 |
| Johnson & Johnson(2 entities) | 154 | $1,626 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Angiodynamics, Inc. | 4 | $776 |
| Teleflex LLC | 10 | $643 |
| Procept Biorobotics Corporation | 7 | $553 |
| Astellas Pharma US Inc | 20 | $349 |
| Medtronic(2 entities) | 5 | $263 |
| Bayer | 11 | $220 |
| Dendreon Pharmaceuticals LLC | 7 | $211 |
| Axonics, Inc. | 11 | $188 |
| AbbVie(2 entities) | 11 | $185 |
| Pfizer | 10 | $183 |
| Sumitomo Pharma America, Inc. | 7 | $166 |
| Travere Therapeutics, Inc. | 6 | $165 |
| Boston Scientific | 6 | $156 |
| Olympus America Inc. | 4 | $124 |
| Novartis | 5 | $105 |
| Urogen Pharma, Inc. | 4 | $67 |
| Calyxo, Inc. | 4 | $66 |
| Ferring Pharmaceuticals Inc. | 4 | $65 |
| Blue Earth Diagnostics | 2 | $61 |
| Palette Life Sciences, Inc. | 1 | $60 |
| Endo Pharmaceuticals Inc. | 3 | $55 |
| AstraZeneca | 3 | $50 |
| Immunitybio, Inc. | 1 | $38 |
| Myriad Genetic Laboratories, Inc. | 2 | $38 |
| Coloplast | 2 | $37 |
| Myovant Sciences Inc. | 2 | $34 |
| Tolmar, Inc. | 1 | $33 |
| Merck | 1 | $32 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Amgen | 2 | $30 |
| Tempus AI, Inc | 1 | $26 |
| Sanofi | 1 | $23 |
| Bluewind Medical | 1 | $21 |
| Valencia Technologies Corporation | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$39,668
- DA VINCI SP$6,500
- Nanoknife$717
- AquaBeam Robotic System$414
- Barrigel$190
- UroLift$149
- Erleada$133
- AKEEGA$133
- INFINITY OCCIPITOCERVICAL UPPER THORACIC SYSTEM$125
- (815) Thiola$122
- UroLift System$106
- RYBREVANT$104
- CARVYKTI$104
How this compares
$54,292 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 157 | $160,497 |
| MyrbetriqMirabegron | 154 | $136,811 |
| Methenamine Hippurate | 81 | $9,610 |
| Mirabegron ErMirabegron | 20 | $7,268 |
| Silodosin | 59 | $5,572 |
| Finasteride | 412 | $4,882 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 141 | $4,639 |
| Tamsulosin Hcl | 357 | $4,197 |
| Dutasteride | 87 | $3,777 |
| Solifenacin Succinate | 93 | $3,199 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,884 |
| Estradiol | 46 | $2,837 |
| Tadalafil | 15 | $1,843 |
| Trimethoprim | 64 | $1,635 |
| Testosterone Cypionate | 28 | $1,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $166 | $160,497157 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $136,811154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.
Other urology in Riverview
- Brian CronsonRiverview$111K
- James AlverRiverview$59K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.